<DOC>
	<DOCNO>NCT00972374</DOCNO>
	<brief_summary>This study evaluate efficacy safety Brimo PS DDS® Applicator System ( 200 μg 400 μg brimonidine tartrate ) visual function patient previous rhegmatogenous macula-off retinal detachment .</brief_summary>
	<brief_title>Safety Efficacy Brimonidine Tartrate Posterior Segment Drug Delivery System Improving Visual Function</brief_title>
	<detailed_description />
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>The maculaoff retinal detachment must cause rupture ( rhegmatogenous etiology ) The repair maculaoff retinal detachment must occur least 6 month Day 1 visit study eye The repair must deem anatomic success require one macular reattachment procedure The visual acuity score must 20/50 20/320 study eye Any sightthreatening ocular condition study eye rupture retinal detachment Anticipated need ocular surgery 12month study period Any injectable , periocular , intravitreal corticosteroid treatment study eye within 6 month prior screen ( eg , triamcinolone acetonide ) Any injectable , periocular , intravitreal antiVEGF treatment study eye within 3 month prior screen ( eg , Avastin Lucentis ) Any infectious condition study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>